Sharkey et al. compared radiation dose estimates for the 90Y- or 177Lu-labeled HSG-peptide IMP-241 after bsMAb pretargeting of GW-39 xenografts, concluding that although 90Y delivers a higher dose to the tumors per administered MBq, at equal absorbed doses to kidneys 177Lu-IMP-241 and 90Y-IMP-241 would potentially enable equal tumor doses [36]. Here, MASTL is linked to neoplasm.